Page 138 - 《中国药房》2024年22期

[18] YANG H T，GAO Y Y，XU D，et al. MEK1 drives onco‐ MiR-16 and miR-26a target checkpoint kinases Wee1 and
genic signaling and interacts with PARP1 for genomic and Chk1 in response to p53 activation by genotoxic stress[J].
metabolic homeostasis in malignant pleural mesothelioma Cell Death Dis，2013，4（12）：e953.
[J]. Cell Death Discov，2023，9（1）：55. [33] SAFA，BAHROUDI Z，SHOOREI H，et al. MiR-1：a com‐
[19] DUBOIS F，BAZILLE C，LEVALLET J，et al. Molecular prehensive review of its role in normal development and
alterations in malignant pleural mesothelioma：a hope for diverse disorders[J]. Biomed Pharmacother，2020，132：
effective treatment by targeting YAP[J]. Target Oncol， 110903.
2022，17（4）：407-431. [34] YUEN M，ZHUANG L，RATH E M，et al. The role of E-
[20] FU M Y，HU Y，LAN T X，et al. The Hippo signalling cadherin and microRNA on FAK inhibitor response in ma‐
pathway and its implications in human health and diseases lignant pleural mesothelioma（MPM）[J]. Int J Mol Sci，
[J]. Signal Transduct Target Ther，2022，7（1）：376. 2021，22（19）：10225.
[21] ANDO T，ARANG N，WANG Z Y，et al. EGFR regulates [35] TANG L，ZHOU L，WU S C，et al. MiR-125a-5p inhibits
the Hippo pathway by promoting the tyrosine phosphory‐ colorectal cancer cell epithelial-mesenchymal transition，
lation of MOB1[J]. Commun Biol，2021，4（1）：1237. invasion and migration by targeting TAZ[J]. Onco Targets
[22] CERSOSIMO F，BARBARINO M，LONARDI S，et al. Ther，2019，12：3481-3489.
Mesothelioma malignancy and the microenvironment：mo‐ [36] ROMANOWICZ H，HOGENDORF P，MAJOS A，et al.
lecular mechanisms[J]. Cancers，2021，13（22）：5664. Analysis of miR-143，miR-1，miR-210 and let-7e expres‐
[23] PANZETTA V，MUSELLA I，FUSCO S，et al. ECM sion in colorectal cancer in relation to histopathological
mechanoregulation in malignant pleural mesothelioma[J]. features[J]. Genes，2022，13（5）：875.
Front Bioeng Biotechnol，2022，10：797900. [37] RUSSO G L，TESSARI A，CAPECE M，et al. Micro-
[24] ZHAO J，LIU B，LIU N，et al. The role of angiogenesis in RNAs for the diagnosis and management of malignant
malignant pleural effusion：from basic research to clinical pleural mesothelioma：a literature review[J]. Front Oncol，
application[J]. Am J Cancer Res，2022，12（11）：4879- 2018，8：650.
4891. [38] FERRARI E，GANDELLINI P. Unveiling the ups and
[25] GEMELLI M，CORTINOVIS D L，BAGGI A，et al. Im‐ downs of miR-205 in physiology and cancer：transcrip‐
mune checkpoint inhibitors in malignant pleural mesothe‐ tional and post-transcriptional mechanisms[J]. Cell Death
lioma：a systematic review and meta-analysis[J]. Cancers， Dis，2020，11（11）：980.
2022，14（24）：6063. [39] YAMAMOTO K，SEIKE M，TAKEUCHI S，et al. MiR-
[26] RAMUNDO V，ZANIRATO G，ALDIERI E. The 379/411 cluster regulates IL-18 and contributes to drug re‐
epithelial-to-mesenchymal transition（EMT）in the deve- sistance in malignant pleural mesothelioma[J]. Oncol Rep，
lopment and metastasis of malignant pleural mesothelioma 2014，32（6）：2365-2372.
[J]. Int J Mol Sci，2021，22（22）：12216. [40] CIOCE M，RUTIGLIANO D，PUGLIELLI A，et al.
[27] DEBNATH P，HUIREM R S，DUTTA P，et al. Epithelial- Butein-instigated miR-186-5p-dependent modulation of
mesenchymal transition and its transcription factors[J]. TWIST1 affects resistance to cisplatin and bioenergetics
Biosci Rep，2022，42（1）：BSR20211754. of malignant pleural mesothelioma cells[J]. Cancer Drug
[28] JOHNSON B，ZHUANG L，RATH E M，et al. Exploring Resist，2022，5（3）：814-828.
microRNA and exosome involvement in malignant pleural [41] WANG Y，WANG M，YU P，et al. MicroRNA-126 modu‐
mesothelioma drug response[J]. Cancers，2022，14（19）：4784. lates palmitate-induced migration in HUVECs by down‐
[29] GOTO A，TANAKA M，YOSHIDA M，et al. The low ex‐ regulating myosin light chain kinase via the ERK/MAPK
pression of miR-451 predicts a worse prognosis in non- pathway[J]. Front Bioeng Biotechnol，2020，8：913.
small cell lung cancer cases[J]. PLoS One，2017，12（7）： [42] SUDHANVA M S，HARIHARASUDHAN G，JUN S，et
e0181270. al. MicroRNA-145 impairs classical non-homologous end-
[30] ANOBILE D P，MONTENOVO G，PECORARO C，et al. joining in response to ionizing radiation-induced DNA
Splicing deregulation，microRNA and Notch aberrations： double-strand breaks via targeting DNA-PKcs[J]. Cells，
fighting the three-headed dog to overcome drug resistance 2022，11（9）：1509.
in malignant mesothelioma[J]. Expert Rev Clin Pharma‐ [43] MOODY H L，LIND M J，MAHER S G. MicroRNA-31
col，2022，15（3）：305-322. regulates chemosensitivity in malignant pleural mesothe‐
[31] LIU Q，FU H J，SUN F，et al. MiR-16 family induces cell lioma[J]. Mol Ther Nucleic Acids，2017，8：317-329.
cycle arrest by regulating multiple cell cycle genes[J]. （收稿日期：2024-04-04 修回日期：2024-11-01）
Nucleic Acids Res，2008，36（16）：5391-5404. （编辑：孙 冰）
[32] LEZINA L，PURMESSUR N，ANTONOV A V，et al.

· 2836 · China Pharmacy 2024 Vol. 35 No. 22 中国药房 2024年第35卷第22期